540 related articles for article (PubMed ID: 17511970)
1. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.
Bortolato M; Mangieri RA; Fu J; Kim JH; Arguello O; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
Biol Psychiatry; 2007 Nov; 62(10):1103-10. PubMed ID: 17511970
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
3. Activation of endocannabinoid transmission induces antidepressant-like effects in rats.
Adamczyk P; Gołda A; McCreary AC; Filip M; Przegaliński E
J Physiol Pharmacol; 2008 Jun; 59(2):217-28. PubMed ID: 18622041
[TBL] [Abstract][Full Text] [Related]
4. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Jhaveri MD; Richardson D; Robinson I; Garle MJ; Patel A; Sun Y; Sagar DR; Bennett AJ; Alexander SP; Kendall DA; Barrett DA; Chapman V
Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
[TBL] [Abstract][Full Text] [Related]
6. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.
Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D
Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159
[TBL] [Abstract][Full Text] [Related]
7. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.
Hasanein P; Shahidi S; Komaki A; Mirazi N
Eur J Pharmacol; 2008 Sep; 591(1-3):132-5. PubMed ID: 18593578
[TBL] [Abstract][Full Text] [Related]
8. URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
Hasanein P; Parviz M; Keshavarz M; Roohbakhsh A
Can J Physiol Pharmacol; 2009 Jun; 87(6):432-9. PubMed ID: 19526037
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like activity and cardioprotective effects of fatty acid amide hydrolase inhibitor URB694 in socially stressed Wistar Kyoto rats.
Carnevali L; Vacondio F; Rossi S; Callegari S; Macchi E; Spadoni G; Bedini A; Rivara S; Mor M; Sgoifo A
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2157-69. PubMed ID: 26391492
[TBL] [Abstract][Full Text] [Related]
10. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
Lee J; Di Marzo V; Brotchie JM
Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597).
Piomelli D; Tarzia G; Duranti A; Tontini A; Mor M; Compton TR; Dasse O; Monaghan EP; Parrott JA; Putman D
CNS Drug Rev; 2006; 12(1):21-38. PubMed ID: 16834756
[TBL] [Abstract][Full Text] [Related]
12. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains.
Bekris S; Antoniou K; Daskas S; Papadopoulou-Daifoti Z
Behav Brain Res; 2005 Jun; 161(1):45-59. PubMed ID: 15904709
[TBL] [Abstract][Full Text] [Related]
13. The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues.
Clapper JR; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
Pharmacol Res; 2006 Nov; 54(5):341-4. PubMed ID: 16935521
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.
Justinova Z; Mangieri RA; Bortolato M; Chefer SI; Mukhin AG; Clapper JR; King AR; Redhi GH; Yasar S; Piomelli D; Goldberg SR
Biol Psychiatry; 2008 Dec; 64(11):930-7. PubMed ID: 18814866
[TBL] [Abstract][Full Text] [Related]
15. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
[TBL] [Abstract][Full Text] [Related]
16. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW
Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291
[TBL] [Abstract][Full Text] [Related]
17. URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.
Maya-López M; Ruiz-Contreras HA; de Jesús Negrete-Ruíz M; Martínez-Sánchez JE; Benítez-Valenzuela J; Colín-González AL; Villeda-Hernández J; Sánchez-Chapul L; Parra-Cid C; Rangel-López E; Santamaría A
Biomed Pharmacother; 2017 Apr; 88():745-753. PubMed ID: 28157650
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant effects of ginseng total saponins in the forced swimming test and chronic mild stress models of depression.
Dang H; Chen Y; Liu X; Wang Q; Wang L; Jia W; Wang Y
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1417-24. PubMed ID: 19632285
[TBL] [Abstract][Full Text] [Related]
19. Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms.
Shahidi S; Hasanein P
Brain Res Bull; 2011 Aug; 86(1-2):118-22. PubMed ID: 21763761
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents.
Xu Q; Yi LT; Pan Y; Wang X; Li YC; Li JM; Wang CP; Kong LD
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):715-25. PubMed ID: 18093712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
